Caffeine and incidence of dyspnea in patients treated with ticagrelor - 11/06/18
Doi : 10.1016/j.ahj.2018.02.011
Daniel Lindholm, MD, PhD ⁎ 
Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden
Uppsala Clinical Research Center, Uppsala, Sweden
⁎Reprint requests: Dr. Daniel Lindholm, MD, PhD, Uppsala Clinical Research Center, Dag Hammarskjölds väg 38, SE-75185 Uppsala.Uppsala Clinical Research CenterDag Hammarskjölds väg 38UppsalaSE-75185
Stefan James, MD, PhD
Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden
Uppsala Clinical Research Center, Uppsala, Sweden
Jonas Andersson, MD, PhD
Heartcenter, Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden
Oscar Ö Braun, MD, PhD
Department of Cardiology, Clinical Sciences, Faculty of Medicine, Lund University, Skåne University Hospital, Lund, Sweden
Peter Henriksson, MD, PhD
Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden
Jörg Lauermann, MD
Department of Internal Medicine, Division of Cardiology, Ryhov Hospital, Jönköping, Sweden
Christoph Varenhorst, MD, PhD
Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden
Pfizer, Stockholm, Sweden
Le texte complet de cet article est disponible en PDF.
| RCT# NCT02311088 |
|
| Conflicts of interest: DL: Reports institutional research grants and consultant fees to the institution from AstraZeneca and institutional research grants from GlaxoSmithKline. SJ: Reports institutional research grant, honoraria, and consultant/advisory board fee from AstraZeneca; institutional research grant and consultant/advisory board fee from Medtronic; institutional research grants and honoraria from The Medicines Company; and consultant/advisory board fees from Janssen and Bayer. JA: Reports no conflicts of interest. OÖB: Reports institutional research grants from AstraZeneca, lecture and advisory board fees from AstraZeneca, Amgen and Bayer and is on the Clinical Endpoint Committee for AstraZeneca. SH: Reports no conflicts of interest. PH: Reports no conflicts of interest. JL: Reports no conflicts of interest. PÖ: Reports no conflicts of interest. CV: received at the time the research was performed institutional research grants from AstraZeneca and The Medicines Company, lecture and advisory board fees from AstraZeneca, The Medicines Company and Boeringer Ingelheim, lecture fees from Bristol Myers Squibb, Pfizer and CSL Behring, and was on the Clinical Endpoint Committee for Pfizer, Bristol Myers Squibb, Philips and AstraZeneca. After the time the research was conducted but before the manuscript was submitted CV reports being a Pfizer employee. |
© 2018
Elsevier Inc. Tous droits réservés.
Vol 200
P. 141-143 - juin 2018 Retour au numéro
Article précédent
- Early impact of guideline publication on angiotensin-receptor neprilysin inhibitor use among patients hospitalized for heart failure
- Nancy Luo, Nicholas G. Ballew, Emily C. O'Brien, Melissa A. Greiner, Pamela N. Peterson, Bradley G. Hammill, N. Chantelle Hardy, Warren K. Laskey, Paul A. Heidenreich, Chun-Lan Chang, Adrian F. Hernandez, Lesley H. Curtis, Robert J. Mentz, Gregg C. Fonarow
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?